INTERNATIONAL PATENT: INTRA-CELLULAR THERAPIES, INC. FILES APPLICATION FOR "LUMATEPERONE AND ANALOGUES, AS 5-HT2A OR 5-HT2A/D2 RECEPTOR MODULATORS, FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS CAUSED BY VIRAL, BACTERIAL, OR AUTOIMMUNE ENCEPHALITIS AND OF PSYCHIATRIC SYMPTOMS THEREOF"

GENEVA, June 4 -- INTRA-CELLULAR THERAPIES, INC. (135 Route 202/206Suite 6Bedminster, New Jersey 07921) filed a patent application (PCT/US2024/057135) for "LUMATEPERONE AND ANALOGUES, AS 5-HT2A OR 5-HT2A/D2 RECEPTOR MODULATORS, FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS CAUSED BY VIRAL, BACTERIAL, OR AUTOIMMUNE ENCEPHALITIS, AND OF PSYCHIATRIC SYMPTOMS THEREOF" on Nov 22, 2024. With publication no. WO/2025/111568, the details related to the patent application was published on May 30, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): DUTHEIL, Sophie (c/o Intra-Cellular Therapies, Inc.135...